Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO

Feb 15 2023

• By Jessica Merrill

Listen to this article

Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

Brent Saunders — Brent Saunders • Source: Bausch + Lomb

Industry veteran Brent Saunders is returning to the pharmaceutical sector and a company he knows particularly well: Bausch + Lomb Inc., the eye specialist where he first cut his teeth as a CEO in 2010. B+L announced the appointment of Saunders to the CEO role on 15 February. He will succeed Joseph Papa, who led the business through some tumultuous years beginning in 2016 when it was still under Bausch Health Companies Inc. and formerly known as Valeant

Much has changed at B+L in the 10 years since Saunders left the company, following its acquisition by Valeant in...

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership
Dec 05 2025
• By Jung Won Shin
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart
Jun 14 2025
• By Nabil
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj